Another German biopharmaceutical company, CureVac specializes in therapies based on mRNA. Specifically, CureVac features a proprietary RNA platform that may “enable the body to make its own prophylactic and therapeutic drugs,” per its website. While an intriguing market idea based on the forward implications of mRNA-based technologies, CVAC presents significant risks, even compared to other clinical-stage biotech stocks.
Since the start of this year, CVAC suffered a catastrophic loss of almost 77%. Even worse, nearer-term momentum implies the pain has yet to abate, with CVAC incurring a 21% loss in the trailing month.
On the financial spectrum as well, CureVac could use some help. In Q2 2022, the company posted revenue of $21.3 million, down 21% from the year-ago quarter. Additionally, CureVac posted a net loss of $60.9 million in the most recent quarter.
However, the development and distribution of mRNA COVID vaccines should theoretically bolster underlying biotech stocks in the long run due to proven viability. Therefore, risk-tolerant investors may want to consider CVAC.
Will CureVac Stock Go Up?
Turning to Wall Street, CVAC stock has a Moderate Buy consensus rating based on two Buys assigned in the past three months. The average CVAC price target is $37, implying 369.50% upside potential.
Market Data 
Markets 
AI
